Gentilella, Raffaella Romera, Irene Nicolay, Claudia Buzzetti, Raffaella Vázquez, Luis Alberto Sesti, Giorgio
Published in
Diabetes Therapy
IntroductionThis exploratory post hoc analysis investigated the relative changes in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) treated with dulaglutide versus active comparators across a continuous range of baseline HbA1c values using data from three phase III randomised controlled trials.MethodsData from patients...
Hamersky, Carol M. Fridman, Moshe Gamble, Cory L. Iyer, Neeraj N.
Published in
Diabetes Therapy
IntroductionImproving real-world medication adherence to injectable antihyperglycemics in type 2 diabetes mellitus (T2DM) is a clinical challenge. Quantification of the level of adherence required to achieve a minimal clinically important difference (MCID) in glycemic control would assist in meeting this goal. The study objective was to review the ...
Hinton, William Feher, Michael D. Munro, Neil de Lusignan, Simon
Published in
Diabetes Therapy
IntroductionSodium-glucose co-transporter-2 (SGLT2) inhibitors are oral antihyperglycemic agents for the treatment of people with type 2 diabetes (T2DM). Two recent cardiovascular outcome trials (CVOTs), the EMPA-REG OUTCOME trial and CANVAS Program, have demonstrated that SGLT2 inhibitors have cardiovascular benefit in high-risk cardiovascular pat...
Chehregosha, Haleh Khamseh, Mohammad E. Malek, Mojtaba Hosseinpanah, Farhad Ismail-Beigi, Faramarz
Published in
Diabetes Therapy
Hemoglobin A1C (HbA1c) is used as an index of average blood glucose measurement over a period of months and is a mainstay of blood glucose monitoring. This metric is easy to measure and relatively inexpensive to obtain, and it predicts diabetes-related microvascular complications. However, HbA1c provides only an approximate measure of glucose contr...
Ohmura, Hirotoshi Mita, Tomoya Matsuoka, Joe Nojiri, Shuko Nishizaki, Yuji Watada, Hirotaka Daida, Hiroyuki
Published in
Diabetes Therapy
IntroductionType 2 diabetes is associated with vascular complications that deteriorate the quality of life and decrease the life expectancy of individuals. We previously reported the efficacy of sitagliptin for glucose control in patients with type 2 diabetes in the Sitagliptin Registration Type 2 Diabetes-Juntendo Collaborating Project (SPIRITS-J)...
Xerfan, Ellen M. S. Tomimori, Jane Albuquerque, Rachel G. Tufik, Sergio Andersen, Monica L.
Published in
Diabetes Therapy
Divino, Victoria Boye, Kristina S. Lebrec, Jeremie DeKoven, Mitch Norrbacka, Kirsi
Published in
Diabetes Therapy
IntroductionThe glucagon-like peptide-1 receptor agonist (GLP-1 RA) class is evolving and expanding. This retrospective database study evaluated recent real-world treatment and dosing patterns of patients with type 2 diabetes (T2D) initiating GLP-1 RAs in Belgium (BE), France (FR), Germany (DE), Italy (IT), the Netherlands (NL), and Canada (CA).Met...
Ping, Fan Deng, Mingqun Zhai, Xiao Song, Yingna Xiao, Xinhua
Published in
Diabetes Therapy
IntroductionGlycemic control in pregnant women with type 1 diabetes (T1D) is challenging with only insulin, and the incidence rate of adverse perinatal outcomes is high. Increasing data have indicated the safety and effect of metformin in pregnancy; however, no relevant data are available in pregnant women with T1D. We aimed to investigate glycemic...
Nørgaard, Kirsten Kielgast, Urd
Published in
Diabetes Therapy
Hirose, Takahisa Chen, Ching-Chu Ahn, Kyu Jeung Kiljański, Jacek
Published in
Diabetes Therapy
AbstractInsulin glargine (IGlar) 100 U/mL (IGlar-100) is widely used in East Asian countries for the treatment of type 2 diabetes mellitus (T2DM) and is the gold standard of basal insulin treatment. In this review we summarize key information about clinical experience with IGlar-100 in East Asian patients with T2DM, including findings from clinical...
